- Home
- YMAB vs RCEL Comparison
YMAB vs RCEL Comparison
Compare YMAB & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- RCEL
- Stock Information
- Founded
- YMAB 2015
- RCEL N/A
- Country
- YMAB United States
- RCEL United States
- Employees
- YMAB N/A
- RCEL N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- RCEL Medical/Dental Instruments
- Sector
- YMAB Health Care
- RCEL Health Care
- Exchange
- YMAB Nasdaq
- RCEL Nasdaq
- Market Cap
- YMAB 218.4M
- RCEL 227.5M
- IPO Year
- YMAB 2018
- RCEL N/A
- Fundamental
- Price
- YMAB $4.69
- RCEL $9.21
- Analyst Decision
- YMAB Buy
- RCEL Strong Buy
- Analyst Count
- YMAB 11
- RCEL 4
- Target Price
- YMAB $18.73
- RCEL $17.25
- AVG Volume (30 Days)
- YMAB 318.1K
- RCEL 201.7K
- Earning Date
- YMAB 05-06-2025
- RCEL 05-08-2025
- Dividend Yield
- YMAB N/A
- RCEL N/A
- EPS Growth
- YMAB N/A
- RCEL N/A
- EPS
- YMAB N/A
- RCEL N/A
- Revenue
- YMAB $87,685,000.00
- RCEL $64,251,000.00
- Revenue This Year
- YMAB N/A
- RCEL $62.33
- Revenue Next Year
- YMAB $21.10
- RCEL $30.59
- P/E Ratio
- YMAB N/A
- RCEL N/A
- Revenue Growth
- YMAB 3.38
- RCEL 28.14
- 52 Week Low
- YMAB $3.86
- RCEL $6.90
- 52 Week High
- YMAB $17.78
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- YMAB 47.75
- RCEL 56.76
- Support Level
- YMAB $4.46
- RCEL $8.15
- Resistance Level
- YMAB $5.44
- RCEL $9.36
- Average True Range (ATR)
- YMAB 0.45
- RCEL 0.67
- MACD
- YMAB 0.07
- RCEL 0.15
- Stochastic Oscillator
- YMAB 52.53
- RCEL 93.90
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.